期刊文献+

HE4、CA125、CA199检测对卵巢癌的诊断意义 被引量:1

下载PDF
导出
摘要 目的探讨人附睾蛋白4(HE4)、癌胚抗原125(CA125)及癌胚抗原199(CA199)联合检测在卵巢癌患者中的诊断价值。方法应用ELISA法检测卵巢癌组、卵巢良性肿瘤组及健康对照组患者血清中HE4水平,采用电化学发光检测CA125、CA199水平。结果3组资料比较,卵巢癌组血清HE4、CA125及CA199浓度水平明显高于其他2组(P〈0.05),而健康对照组和良性痛变组比较差异无统计学意义(P〉0.05)。卵巢癌诊断中的阳性率分别是:HE4为68.33%、CA125为63.33%、CA199为60.00%,HE4+CA125为85.00%,HE4+CA199为83.33%,CA125+CA199为78.33%,HE4+CA125+CA199为91.67%。结论HE4、CA125、CA199在卵巢癌诊断中有重要意义,联合检测能明显提高卵巢癌的诊断率。
出处 《检验医学与临床》 CAS 2015年第A01期252-254,共3页 Laboratory Medicine and Clinic
  • 相关文献

参考文献9

  • 1Arik D, Kulacoglu S. P53, bcl-2, and nm23 expressions in serous ovarian tumors: correlation with the clinical andhistopathological parameters E J 1. Turk Patoloji Derg, 2011,27(1) :38-45.
  • 2Pickle LW,Hao Y,Jemal A,et al. A new method of esti mating United States and state level cancer incidence counts for the current calendar year Ej~]. CA Cancer J Clin,2007,57(1) :30 42.
  • 3Clarke-Pearson DL. Clinical practice. Screening for ovari an cancer[-J3. N Engl J Med,2009,361(2) :170-177.
  • 4栾晓蕊,李卫平,狄文.卵巢癌早期诊断的血清肿瘤标志物研究进展[J].国际妇产科学杂志,2009,36(6):458-461. 被引量:46
  • 5Galgano MT, Hampton GM,Frierson HF Jr. Comprehen- sive analysis of HE4 expression in normal and malignant human tissuesEJ2. Mod Pathol, 200G, 19 (6) : 847-853.
  • 6Bingle L, Singleton V, Bingle CD. The putative ovarian turnour marker gene HE4 (WFDC2), is expressed in nor ma| tissues and undergoes complex alternative splicing toyield multiple protein isoforms [J]. Oncogene, 2002, 21 (17) :2768-2773.
  • 7Ke PY, Hu CM, Chang YC, Chang ZF. Hiding human thymidine kinase 1 from APC/C-mediated destruction by thymidine binding~J~. FASEB J, 2007,21 (4) : 1276-1284.
  • 8Topolcan O, Holubec L Jr. The role of thymidine kinase in cancer diseasesEJ~. Expert ()pin Med Diagn, 2008, 2 (2) :129-141.
  • 9Chen ZH, Huang SQ,Wang Y, et al. Serological thymi- dine kinase 1 is a biomarker for early detection of tumours-a health screening study on 35,365 people, u- sing a sensitive chemiluminescent dot blot assayFJ]. Sen sors(Basel) ,2011,11(12) : 11064-11080.

二级参考文献20

  • 1Maeda T, Inoue M, Koshiba S, et al. Solution structure of the SEA domain from the murine homologue of ovarian cancer antigen CA125(MUC16) [J]. J Biol Chem, 2004, 279( 13): 13174-13182.
  • 2Benjapibal M, Neungton C. Pre-operative prediction of serumCA125 level in women with ovarian masses [J]. J Med Assoc Thai, 2007, 90( 10): 1986-1991.
  • 3Menon U, Skates SJ, Lewis S, et al. Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer [J]. J Clin Oncol, 2005, 23 (31 ): 7919-7926.
  • 4Moore RG, Brown AK, Miller MC, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass [J ]. Gynecol Oncol, 2008, 108 (2):402-408.
  • 5Zhang Z, Yu Y, Xu F, et al. Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer [J ]. Gynecol Oncol, 2007, 107(3): 526-531.
  • 6Visintin I, Feng Z, Longton G, et al. Diagnostic markers for early detection of ovarian cancer [J]. Clin Cancer Res, 2008, 14 (4): 1065-1072.
  • 7Bertenshaw GP, Yip P, Seshaiah P, et al. Multianalyte profiling of serum antigens and autoimmune and infectious disease molecules to identify biomarkers dysregulated in epithelial ovarian cancer [J]. Cancer Epidemiol Biomarkers Prey, 2008, 17(10): 2872-2881.
  • 8Drapkin R, von Horsten HH, Lin Y, et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas [J]. Cancer Res, 2005, 65 (6): 2162-2169.
  • 9Ho M, Hassan R, Zhang J, et al. Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients [J]. Clin Cancer Res, 2005, 11 ( 10): 3814-3820.
  • 10Hassan R, Remaley AT, Sampson ML, et al. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer[J]. Clin Cancer Res, 2006, 12(2): 447-453.

共引文献45

同被引文献6

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部